Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04888988 · ClinicalTrials.gov registry record · NA

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by University of Rochester NCORP Research Base.

Active
Registry status
NA
Development phase
133
Enrollment target
20
Study locations

NCT04888988 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by University of Rochester NCORP Research Base. The registered enrollment target is 133 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04888988, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by University of Rochester NCORP Research Base.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
133 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treating CIPN is treatment with drugs that help reduce symptoms of other types of neuropathy (for example, from diabetes). However, these drugs do not treat all symptoms of CIPN. Exercise may help to reduce CIPN symptoms.

Interventions

  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Exercise Intervention
  • OTHER Best Practice
  • OTHER Exercise Counseling
  • OTHER Neuropathy Assessment

Study Locations (20)

California

  • Kaiser Permanente-Fresno - Fresno
  • Contra Costa Regional Medical Center - Martinez
  • Kaiser Permanente-Roseville - Roseville
  • Kaiser Permanente Downtown Commons - Sacramento
  • Kaiser Permanente-South Sacramento - Sacramento
  • Kaiser Permanente-Santa Teresa-San Jose - San Jose
  • Kaiser Permanente San Leandro - San Leandro
  • Kaiser San Rafael-Gallinas - San Rafael
  • Kaiser Permanente Medical Center - Santa Clara - Santa Clara
  • Kaiser Permanente-South San Francisco - South San Francisco
  • Kaiser Permanente-Vallejo - Vallejo
  • Kaiser Permanente-Walnut Creek - Walnut Creek

Colorado

  • Rocky Mountain Cancer Centers-Aurora - Aurora
  • Boulder Community Foothills Hospital - Boulder
  • Rocky Mountain Cancer Centers-Boulder - Boulder
  • Rocky Mountain Cancer Centers - Centennial - Centennial
  • The Women's Imaging Center - Denver
  • Colorado Blood Cancer Institute - Denver
  • Rocky Mountain Cancer Centers-Midtown - Denver
  • Rocky Mountain Cancer Centers-Rose - Denver

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2022-02-25
Est. Completion 2026-02-01
Phase NA

What the Registry Record Tells You About NCT04888988

The ClinicalTrials.gov registry entry for NCT04888988 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (88% lower). The listed sponsor is University of Rochester NCORP Research Base, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT04888988 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04888988 about?

NCT04888988 is a clinical study titled "Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy". This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treatin...

What is the current status of trial NCT04888988?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 133 participants. The study started on 2022-02-25. Estimated completion is 2026-02-01.

What conditions does trial NCT04888988 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Chemotherapy-induced Peripheral Neuropathy.

What interventions are being tested in trial NCT04888988?

The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Exercise Intervention (OTHER), Best Practice (OTHER), Exercise Counseling (OTHER), Neuropathy Assessment (OTHER).

Who is sponsoring clinical trial NCT04888988?

This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04888988 being conducted?

This trial has 20 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.